Latest
Increased Infection, Reduced Hematopoietic Stem Cell Transplantation Rates Seen in TP53-Mutated MDS/AML
FDA Issues Complete Response Letter for Ruxolitinib Extended-Release Tablets
Lucira COVID-19 & Flu Home Test Now Available for OTC Use
One in Seven Nonelderly Adults Have Past-Due Medical Debt
Valemetostat Shows Promising Efficacy in Relapsed/Refractory Adult T-cell Leukemia/Lymphoma
Secreted Mutant Calreticulins Act as Cytokines in Myeloproliferative Neoplasms
Joenja Approved for Activated Phosphoinositide 3-Kinase Delta Syndrome
Anti-GPRC5D CAR-T Therapy Elicits Responses After Anti-BCMA CAR Failure
Viral, Symptom Rebound Common After COVID-19 Infection
On-Demand Treatment With B-Domain-Deleted Recombinant Factor VIII Effective in Hemophilia A
Hydroxyurea Does Not Appear to Increase Second Malignancy Risk in Myeloproliferative Neoplasms
Nirmatrelvir-Ritonavir Effective Against Omicron BA.4, BA.5 SARS-CoV-2 Variant
Featured Content
Helping Clinicians Cope With Moral Distress Can Improve Patient Care
A central objective of addressing moral distress is to permit clinicians to effectively perform their professional functions and thus better help patients.
Ponatinib Linked With Better Outcomes Than Imatinib in Philadelphia Chromosome-Positive ALL
The phase 3 PhALLCON trial showed a trend toward improved EFS in patients with Ph+ newly diagnosed ALL when treated with ponatinib compared with imatinib.
Peer Support Essential for Young Adults Recovering From Cancer Treatment
A review of the importance family, friends, and a support system have on the cancer journey and survival outcomes for young adults with cancer.
EAHAD 2023: Treatments Show Promise for Hemophilia A and B
At EAHAD 2023, researchers reported positive results from trials of patients with hemophilia A and B, including those who are difficult to treat.
- Loading...
Loading...
Loading... 
Loading...